Chemclin Diagnostics released its 2026 interim report, showing first-half net profit attributable to the parent of 15.54 million yuan, down 36.2% year on year. Operating revenue was 154 million yuan, down 6.2% year on year. Net profit attributable to the parent excluding non-recurring items was 9.57 million yuan, down 39.9% year on year. Net operating cash flow was 52.74 million yuan, up 32.6% year on year. Earnings per share were 0.0387 yuan. In the second quarter, operating revenue was 81.12 million yuan, down 2.6% year on year. Net profit attributable to the parent was 6.58 million yuan, down 32.9% year on year. Net profit attributable to the parent excluding non-recurring items was 1.97 million yuan, down 58.8% year on year. As of the end of the second quarter, total assets were 1.77 billion yuan, up 0.5% from the end of the previous year. Net assets attributable to the parent were 1.426 billion yuan, up 1.1% from the end of the previous year. The company said its LiCA series products have received good market feedback, and noted that its new-generation HIV antigen and antibody detection reagent, a domestic first, uses a double-antibody and double-antigen sandwich technique that can distinguish recent infection from past infection.
Chemclin Diagnostics Co. Ltd. AFirst-half net profit attributable to parent fell 36.2% to 15.54 million yuan, with revenue down 6.2%.
Zhuhai Comleader Information Science & Technology Co. Ltd. A